Madhuri Vusirikala

Company: Actinium Pharmaceuticals

Job title: VP, Clinical Development, BMT and Cellular Therapy

Seminars:

Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/ Refractory AML Using Antibody Radiation Conjugates (ARC) 11:45 am

Exploring Iomab-B, a CD45 I-131 ARC, enables bone marrow transplant in otherwise ineligible patients, while Actimab-A, a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity Outlining how responses in heavily pretreated patients for both Iomab-B and Actimab-A, including prior venetoclax treatment or TP53-mutant disease, demonstrate how targeted radiotherapies offer broad therapeutic potential as backbone regimens Revealing…Read more

day: Day One Discovery AM